SAHA is a pan-HDAC inhibitor, and it was found to significantly inhibit the progression of ovarian cancer-harboring ARID1A mutations and to significantly prolong the survival of tumor-inoculated mice. The gene discussed is ARID1A; the disease is neoplasm.